Cell News and Research

RSS

FDA approves APP Pharmaceuticals' Idarubicin HCI injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.

10 Aug 2009

Discovery of 'marker' molecule offers hope for liver cancer test

Cancer Research UK scientists have discovered a 'marker' molecule which could pinpoint when liver cells start to become cancerous, reveals research published in Science*.

9 Aug 2009

Chemists rationally design inhibitors against an RNA molecule that causes myotonic muscular dystrophy

Chemists at the University at Buffalo have used rational drug design to synthesize small, cell-permeable molecules that are effective in vitro against two common types of myotonic muscular dystrophy, a result that has implications for potentially curing muscular dystrophy, as well as other diseases.

9 Aug 2009

Psychology of weight regulation - eating, exercise, and body image

Childhood obesity has quadrupled in the last 40 years, which may mean today's children become the first generation to have a shorter lifespan than their parents, a leading obesity expert told the American Psychological Association on Saturday.

9 Aug 2009

NIH stimulus funding supports Emory - grants to advance research, create jobs, support students

At least 50 research projects so far, supported by more than $10 million in stimulus grants from the National Institutes of Health, are expected to lead to new discoveries at Emory University that will improve medical treatment, create new jobs, and provide additional educational opportunities for students. Emory has received half of all the NIH ARRA grants awarded to Georgia academic institutions thus far.

9 Aug 2009

Female supervisors more likely to be sexually harassed at work

Women who hold supervisory positions are more likely to be sexually harassed at work, according to the first-ever, large-scale longitudinal study to examine workplace power, gender and sexual harassment.

9 Aug 2009

Only two stem cell lines account for most human embryonic stem cell research

For the past eight years, scientists who wanted to use federal funds for research on human embryonic stem cells had to restrict their studies to 21 cell lines approved by the National Institutes of Health. But an analysis by a researcher at the Stanford University School of Medicine suggests that only two of those lines have been used routinely.

7 Aug 2009

Immune system protects cancer cells in first few days

During the very first few days of development of a cancer, our immune system recognizes cancer cells not as abnormal cells requiring eradication but as cells of the body that need to be protected. This result was obtained by the team led by David Klatzmann at the Laboratoire Immunologie (UPMC / CNRS / INSERM).

7 Aug 2009

Two significant advances in treating lung cancer

Dr. Glen Weiss of the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare this week announced two significant advances in treating lung cancer at an international cancer research conference.

7 Aug 2009

More insulin-producing cells from a single transcription factor switch

Researchers have found a way in mice to convert another type of pancreas cell into the critical insulin-producing beta cells that are lost in those with type I diabetes. The secret ingredient is a single transcription factor, according to the report in the August 7th issue of Cell, a Cell Press journal.

7 Aug 2009

Changes in mtDNA can cause premature ageing

The normal ageing process has long been linked to problems with cell respiration, the process through which the cells extract energy from nutrients. Researchers at the Swedish medical university Karolinska Institutet have now shown how certain proteins that are synthesised in the cellular mitochondria - popularly known as the cells' power plants - become unstable and disintegrate, which in turn can impair cell respiration and cause premature ageing.

7 Aug 2009

Scientists find key to strengthening immune response to chronic infection

A team of researchers from The Wistar Institute has identified a protein that could serve as a target for reprogramming immune system cells exhausted by exposure to chronic viral infection into more effective "soldiers" against certain viruses like HIV, hepatitis C, and hepatitis B, as well as some cancers, such as melanoma.

6 Aug 2009

Proteomics helps find key to keeping cells in shape

Yale University researchers have discovered how a protein within most cell membranes helps maintain normal cell size, a breakthrough in basic biology that has implications for a variety of diseases such as sickle cell anemia and disorders of the nervous system.

6 Aug 2009

Senators Harkin, Kennedy and Specter honored as champions of health research

The Foundation for the National Institutes of Health, Research!America and the Albert and Mary Lasker Foundation recognized these three senators for their continued support of research for health, their leadership and shared commitment to making it a high national priority, on Tuesday evening August 4th at the Russell Senate Office Building.

6 Aug 2009

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.

6 Aug 2009

Discovery of common trigger in cancer and normal stem cell reproduction

Researchers at Stanford University School of Medicine have discovered, for the first time, a common molecular pathway that is used by both normal stem cells and cancer stem cells when they reproduce themselves.

6 Aug 2009

Thermogenesis expands collaboration with Celling Technologies

ThermoGenesis has announced an expanded collaboration with Celling Technologies, a subsidiary of SpineSmith, LLC, related to the Company's bone marrow products, MXP(TM) MarrowXpress(TM) and Res-Q(TM) 60 BMC. Celling is a leading distributor of orthopedic products, based in Texas.

6 Aug 2009

GE Global Research Biosciences technology celebrated fifth anniversary

From creating a new business in digital pathology to developing next generation diagnostic imaging agents and life sciences tools that are breaking new ground in the detection and treatment of disease, the Biosciences technology organization at GE Global Research today celebrated its fifth anniversary.

6 Aug 2009

Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine

Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is being conducted under a Bellicum Investigational New Drug application allowed by the FDA in 2008. The company anticipates reporting initial results of the study in 2010.

6 Aug 2009

Genetic profiling of tumors could have 'immediate impact' on treating cancer

New work by MIT cancer biologists shows that the interplay between two key genes that are often defective in tumors determines how cancer cells respond to chemotherapy.

6 Aug 2009